COX-2, another important player in the nitric oxide-endothelin cross-talk: Good news for COX-2 inhibitors?

Circulation Research

Volumn 98, Issue 11, 2006, Pages 1344-1346

  Hink, Ulrich ^a   Münzel, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

COX 2; Endothelin; Prostanoids

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN 4; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; G PROTEIN COUPLED RECEPTOR; INDOMETACIN; NITRIC OXIDE; NITRIC OXIDE DONOR; PROSTACYCLIN; STATINE DERIVATIVE; UNCLASSIFIED DRUG; PEPTIDE FRAGMENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR RISK; EDITORIAL; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HUMAN; HYPERTENSION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; VASOCONSTRICTION; VASODILATATION; ANIMAL; CHEMISTRY; DRUG EFFECT; DRUG POTENTIATION; NOTE; PHYSIOLOGY;

ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; ENDOTHELIN-1; ENDOTHELINS; HUMANS; NITRIC OXIDE; PEPTIDE FRAGMENTS; RECEPTOR, ENDOTHELIN A; VASOCONSTRICTION;

EID: 33745368045     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000228471.38761.93     Document Type: Editorial

References (19)

1. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-tenn follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101:948-954.
2. Bernatova I, Pechanova O, Pelouch V, Simko F. Regression of chronic L-NAME-treatment-induced left ventricular hypertrophy: effect of captopril. J Mol Cell Cardiol. 2000;32:177-185.
3. Devlin AM, Brosnan MJ, Graham D, Morton JJ, McPhaden AR, McIntyre M, Hamilton CA, Reid JL, Dominiczak AF. Vascular smooth muscle cell polyploidy and cardiomyocyte hypertrophy due to chronic NOS inhibition in vivo. Am J Physiol. 1998;274:H52-H59.
4. da Cunha V, Rossoni LV, Oliveira PA, Poton S, Pretti SC, Vassallo DV, Stefanon I. Cyclooxygenase inhibition reduces blood pressure elevation and vascular reactivity dysfunction caused by inhibition of nitric oxide synthase in rats. Clin Exp Hypertens. 2000;22:203-215.
5. Kahler J, Mendel S, Weckmuller J, Orzechowski HD, Mittmann C, Koster R, Paul M, Meinertz T, Munzel T. Oxidative stress increases synthesis of big endothelin-1 by activation of the endothelin-1 promoter. J Mol Cell Cardiol. 2000;32:1429-1437.
6. Kahler J, Ewert A, Weckmuller J, Stobbe S, Mittmann C, Koster R, Paul M, Meinertz T, Munzel T. Oxidative stress increases endothelin-1 synthesis in human coronary artery smooth muscle cells. J Cardiovasc Pharmacol. 2001;38:49-57.
7. Ruef J, Moser M, Kubler W, Bode C. Induction of endothelin-1 expression by oxidative stress in vascular smooth muscle cells. Cardiovasc Pathol. 2001;10:311-315.
8. Munzel T, Giaid A, Kurz S, Stewart DJ, Harrison DG. Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance. Proc Natl Acad Sci U S A. 1995;92:5244-5248.
9. Rajagopalan S, Laursen JB, Borthayre A, Kurz S, Keiser J, Haleen S, Giaid A, Harrison DG. Role for endothelin-1 in angiotensin II-mediated hypertension. Hypertension. 1997;30:29-34.
10. Warner TD, Mitchell JA, de Nucci G, Vane JR Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. J Cardiovasc Pharmacol. 1989;13 Suppl 5:S85-S88; discussion S102.
11. Hirata Y, Emori T, Eguchi S, Kanno K, Imai T, Ohta K, Marumo F. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest. 1993;91:1367-1373.
12. Hink U, Oelze M, Kolb P, Bachschmid M, Zou MH, Daiber A, Mollnau H, August M, Baldus S, Tsilimingas N, Walter U, Ullrich V, Munzel T. Role for peroxynitrite in the inhibition of prostacyclin synthase in nitrate tolerance. J Am Coll Cardiol. 2003;42:1826-1834.
13. Chen D, Balyakina EV, Lawrence M, Christman BW, Meyrick B. Cyclooxygenase is regulated by ET-1 and MAPKs in peripheral lung microvascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2003;284:L614-L621.
14. Desjardins F, Aubin MC, Carrier M, Perrault LP. Decrease of endothelin receptor subtype ETB and release of COX-derived products contribute to endothelial dysfunction of porcine epicardial coronary arteries in left ventricular hypertrophy. J Cardiovasc Pharmacol. 2005;45:499-508.
15. Zhou Y, Mitra S, Varadharaj S, Parinandi N, Zweier JL, Flavahan NA. Increased expression of cyclooxygenase-2 mediates enhanced contraction to endothelin ETA receptor stimulation in endothelial nitric oxide synthase knockout mice. Circ Res. 2006;98:1439-1445.
16. Taddei S, Virdis A, Ghiadoni L, Salvetti A. Vascular effects of endothelin-1 in essential hypertension: relationship with cyclooxygenase-derived endothelium-dependent contracting factors and nitric oxide. J Cardiovasc Pharmacol. 2000;35:S37-S40.
17. Chataigneau T, Feletou M, Huang PL, Fishman MC, Duhault J, Vanhoutte PM. Acetylcholine-induced relaxation in blood vessels from endothelial nitric oxide synthase knockout mice. Br J Pharmacol. 1999;126:219-226.
18. Spektor G, Fuster V. Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk-where are we now? Nat Clin Pract Cardiovasc Med. 2005;2:290-300.
19. Pidgeon GP, Tamosiuniene R, Chen G, Leonard I, Belton O, Bradford A, Fitzgerald DJ. Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2. Circulation. 2004;110:2701-2707.